Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024
Evaluation Of Talazoparib, a PARP Inhibitor, In Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination with Antibody Therapies in Patients with Advanced Hematologic Cancers
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Molecular Pathogenesis of Plasma Cell Disorder
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Study Summary
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 29, 2024
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 26, 2024
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 21, 2024